TapImmune Inc. stock has blossomed in the month since it announced it will merge with a company producing similar cancer-fighting treatments.
TapImmune will pursue a new approach to treating cancer through a proposed merger with privately held Marker Therapeutics, a WBB Securities analyst said in an upgrade note.
History could be repeating itself and TapImmune (NASDAQ:TPIV) could be Kite 2.0.
TapImmune would consider a partnership deal with a major pharmaceutical firm overseas.
Markers’ platform has shown promise in early clinical trials in lymphoma, acute myeloid leukemia (AML), and multiple myeloma.
TapImmune has entered into a definitive merger agreement to acquire Marker Therapeutics, a privately-held clinical-stage developer of a transformative, non-genetically engineered, multi-antigen T cell therapy platform.
TapImmune has entered in a definitive agreement to acquire Marker Therapeutics.
Clinicians in the not-too-distant future may have something new to offer women with breast cancer and ovarian cancer in whom initial therapy fails to yield a response.
TapImmune will be hosting an investor breakfast at the Blackstone hotel tomorrow, May 17th from 7:30am-10am. Come and meet with with Marker Co-Founders Juan Vera, M.D. and Ann Leen, Ph.D., and former President of the American Society for Gene and Cell Therapy Malcolm Brenner along with TapImmune Management.
TapImmune has snapped up privately-owned Marker Therapeutics to create a new company based on a non-genetically engineered, multi-antigen T cell therapy platform.